Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model.

ABSTRACT:

Background

3-bromopyruvate (3-BrPA) is a glycolytic inhibitor that affects cancer cells by targeting energy metabolism. Preclinical reports have established that a 1.75 mM dose of 3-BrPA is effective and sufficient to inhibit tumor growth when administered under a loco-regional approach (intraarterial and intratumoral). This loco-regional therapeutic dose was found to be nontoxic when given systemically as well. Yet, the mechanism underlying this lack of toxicity of 1.75 mM 3-BrPA during systemic delivery is unknown. Here, we investigated the mechanism associated with the lack of organ toxicity when 1.75 mM 3-BrPA was administered systemically using radiolabeled (14C)-3-BrPA in Sprague-Dawley rats.

Findings

Data obtained from tissue-autoradiography of rats infused with 14C-3

SUBMITTER: Kunjithapatham R 

PROVIDER: S-EPMC3728150 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature